Updates are available Correction dated 2025-05-27
Click to view Correction: https://doi.org/10.1007/s11914-025-00916-3
-
Authors
Palermo, Andrea https://orcid.org/0000-0002-1143-4926
Naciu, Anda Mihaela https://orcid.org/0000-0002-4576-3381
Donovan, Yu Kwang Tay https://orcid.org/0000-0002-2192-2245
Tabacco, Gaia https://orcid.org/0000-0002-6808-0700
Zavatta, Guido https://orcid.org/0000-0003-3657-2070
- License Information
-
More Information
Article History
Accepted: 12 February 2025
First Online: 22 February 2025
Change Date: 17 April 2025
Change Type: Update
Change Details: The original online version of this article was revised: In the original version of this article, the FDA and EMA label indications for palopegteriparatide and rhPTH(1-84) were inadvertently exchanged in Table 1. The table has been corrected. The Authors sincerely apologize for this error.
Change Date: 27 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11914-025-00916-3
Declarations
:
: Statements and Declarations: AP: advisory board for Ascendis Pharma; speakers bureau for Ascendis Pharma. GZ: advisory board for Ascendis Pharma; speakers bureau for Ascendis Pharma. AMN, YKD AND GT have nothing to disclose.
